Hydroxy Itraconazole is the primary active metabolite of Itraconazole, an antifungal medication. It exerts its antifungal effects by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes, leading to disruption of fungal growth and replication. This mechanism makes it effective against a broad spectrum of fungal pathogens, including those responsible for systemic infections such as aspergillosis, candidiasis, and histoplasmosis. As the active form, it contributes to the long-lasting therapeutic effects of Itraconazole in patients requiring prolonged antifungal treatment. It is also relevant in veterinary medicine for managing fungal infections in animals and is under investigation for its potential in addressing antifungal-resistant strains.